Family Offices Quietly Power Biotech's Funding Comeback, Backing Gene Therapy and AI-Driven Drug Discovery
核心洞察
In August, family offices executed 52 direct investments in private companies, with biotech startups representing roughly 20% of transactions, according to Fintrx data.
Stanley Druckenmiller's Duquesne Family Office (搜索) joined a $90 million Series C for Epicrispr Biotechnologies (搜索), which is developing a gene therapy for facioscapulohumeral muscular dystrophy (搜索) (FSHD).
Jeff Bezos's family office and Bill Gates's Gates Frontier (搜索) participated in a $188 million Series E for LifeMine Therapeutics (搜索), which applies AI to fungal genomes for drug discovery.
Investment firms of ultra-wealthy families are helping fuel the venture capital rebound in biotechnology, according to data provided exclusively to CNBC by Fintrx, a private wealth intelligence platform. In August, family offices made 52 direct investments in private companies, with biotech startups representing about 20% of transactions.
The influx of family-office capital is reshaping the funding landscape for early-stage drug developers, with a particular emphasis on gene therapy and artificial intelligence-driven discovery platforms.
Duquesne Family Office Backs Epicrispr's Gene Therapy
Stanley Druckenmiller's Duquesne Family Office (搜索), one of the most active family offices in the U.S., has backed at least four pharmaceuticals or life sciences companies this year, according to Fintrx. Last month, Duquesne participated in a $90 million Series C round for Epicrispr Biotechnologies (搜索).
The 8-year-old startup is pioneering a new gene therapy for a rare muscle disorder known as facioscapulohumeral muscular dystrophy (搜索), or FSHD. The investment underscores growing family-office appetite for companies targeting genetically defined, high-unmet-need conditions.
Druckenmiller said in January that Duquesne had made substantial investments in biotech due to the potential of artificial intelligence. "I knew because I've been on the board of Memorial Sloan Kettering for 30 years, that probably the best use case out there of AI is biotech through drug discovery, diagnostics, monitoring everything," he said in an interview conducted by Morgan Stanley.
Bezos and Gates Join LifeMine's $188 Million Round
In August, the namesake family office of Jeff Bezos also joined a $188 million Series E for LifeMine Therapeutics (搜索), which uses AI to analyze fungal genomes to develop new drugs. LifeMine is currently testing a drug compound to prevent organ failure in transplant recipients.
Bill Gates' venture capital firm, Gates Frontier (搜索), also participated in the megaround, reflecting broad high-net-worth interest in AI-native drug discovery platforms.
A Five-Year High in Biopharma Funding
Venture funding for biotechnology has rebounded strongly this year. U.S. and European biopharma startups raised $12.6 billion in the first half of 2026, a five-year high, according to analysis by Silicon Valley Bank, now a division of First Citizens Bank after its 2023 collapse and subsequent sale.
That said, investors are writing fewer checks overall, especially for early-stage startups, with a greater share of funding going toward companies with drugs already in testing, according to SVB's analysis, citing its own data and data from PitchBook. This shift suggests family offices and other investors are prioritizing de-risked, clinical-stage assets over preclinical bets.